South Korea Next-Generation Cancer Therapeutics Market Size, Share, Growth, and Industry Analysis, By Therapy Type (Targeted Therapy (Small Molecule Inhibitors), Immunotherapy Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) CAR-T Cell Therapy Cancer Vaccines, Gene Therapy, Cell Therapy (e.g., TILs, NK cells) ), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers (Leukemia, Lymphoma, Myeloma) ) and Forecast, 2026-2034

South Korea Next-Generation Cancer Therapeutics Market Trends

Precision Oncology, ADCs and Engineered Cellular Medicines Reshape Treatment

Precision treatment is shifting from broad cytotoxic regimens toward biomarker-defined combinations involving PD-1/PD-L1 blockade, kinase inhibitors, ADCs and engineered immune cells. Korea's 282,047 annual cancer diagnoses create a substantial addressable treatment population, while localized-stage diagnosis increased from 45.6% in 2005 to 50.9% in 2022. Five-year relative survival reached 72.9%, supporting longer treatment pathways and greater utilization of sequential targeted medicines.

Cellular medicine is moving beyond experimental infrastructure. Samsung Medical Center reported 200 CAR-T treatment cases by February 2025 and a 59% treatment-response rate versus 52% reported in the referenced international Phase II study. Meanwhile, CLDN18.2-directed ADC development illustrates the technology transition toward tumor-selective payload delivery; a 2026 study reported a 25.5% overall response rate among 51 evaluated patients and a 58.8% disease-control rate.

South Korea Next-Generation Cancer Therapeutics Market Drivers

High Cancer Burden and Improving Survival Expand Advanced-Treatment Utilization

Korea's 282,047 new cancer cases in 2022, 83,378 deaths and cancer prevalence exceeding 2.59 million people create sustained therapeutic requirements. The age-standardized incidence rate stood at 287.0 per 100,000 and mortality at 65.7 per 100,000. Improved five-year survival of 72.9%, combined with localized-stage diagnosis reaching 50.9%, increases the population eligible for prolonged molecularly guided treatment, maintenance therapy and combination regimens.

South Korea Next-Generation Cancer Therapeutics Market Restraints

Complex Manufacturing and Patient-Specific Delivery Constrain Scale

Autologous cellular therapies require collection, genetic modification, quality control and specialist administration, limiting throughput compared with oral targeted agents. Samsung Medical Center's milestone of 200 CAR-T cases demonstrates expanding capability but also illustrates concentrated treatment infrastructure. Clinical outcomes require specialized management: its reported 59% response rate was 7 percentage points above the 52% comparator response, reinforcing the importance of experienced multidisciplinary centers rather than unrestricted community delivery.

South Korea Next-Generation Cancer Therapeutics Market Opportunities

Tumor-Agnostic Targeting and RNA Platforms Open New Treatment Pools

Pan-tumor therapies, molecular diagnostics and RNA medicines can extend treatment beyond organ-defined oncology. Nationally, 50.9% of cancers were localized at diagnosis in 2022, and survival reached 72.9%, creating larger populations for biomarker testing and sequential intervention. CLDN18.2 ADC research involving 51 patients produced a 25.5% response rate and 58.8% disease-control rate, while Asian patients represented 24 evaluated participants, illustrating the expanding role of molecularly selected Asian populations in global development.

Challenges in South Korea Next-Generation Cancer Therapeutics Market

Clinical Translation Must Keep Pace with Rapid Platform Innovation

The challenge is converting laboratory innovation into scalable clinical access while controlling toxicity, manufacturing and evidence requirements. Korea reported 282,047 new cancer cases but advanced cellular delivery remains concentrated in major hospitals. At Samsung Medical Center, 200 CAR-T cases had been completed by early 2025, with a 59% response rate. Meanwhile, first-in-human CLDN18.2 ADC development planned for 191 participants across Phase I/II settings demonstrates the larger evidence packages increasingly required for next-generation modalities.

South Korea Next-Generation Cancer Therapeutics Market Segmentation

Therapy segmentation shows targeted therapy holding approximately 36.5% of 2026 revenue, followed by immunotherapy at 20.0% and gene therapy at 15.4%. Cancer-type segmentation is led by lung cancer at approximately 28.0%, colorectal cancer at 24.8% and breast cancer at 18.0%.

By Therapy Type

Targeted therapy is the largest therapy category, rising from USD 608.30 million in 2025 to USD 653.13 million in 2026 and USD 1,153.62 million by 2034 at a 7.37% CAGR. Its approximately 36.5% 2026 contribution reflects broad applicability of small-molecule inhibitors across biomarker-defined malignancies.

RNA-based therapy is the fastest-expanding category at an 8.04% CAGR, ahead of gene therapy at 7.73%, cell therapy at 7.58%, ADCs at 7.48% and immunotherapy at 7.34%. RNA therapeutics reach USD 216.53 million in 2034 from USD 116.64 million in 2026.

By Cancer Type

Lung cancer is the largest indication, generating USD 501.03 million in 2026 from USD 467.68 million in 2025 and reaching USD 869.26 million by 2034 at 7.13% CAGR. It represents approximately 28.0% of the cancer-type total in 2026.

Pan-tumor therapeutics record the fastest 8.13% CAGR, followed by brain cancer at 8.07% and prostate cancer at 7.66%. Pan-tumor revenue increases from USD 91.71 million in 2026 to USD 171.38 million by 2034.

By Modality

Monotherapy remains important for biomarker-selected disease, while combination therapy increasingly integrates immunotherapy plus targeted drugs, chemotherapy plus ADCs and mRNA plus checkpoint inhibitors. National cancer survival of 72.9% and more than 2.59 million prevalent cases support longer treatment sequences and combination exposure.

Combination regimens are increasingly investigated to overcome resistance and improve durability. In CLDN18.2-directed ADC research, overall response reached 25.5% and disease control 58.8% among 51 patients, demonstrating the measurable efficacy benchmarks against which future combinations will compete.

By Route of Administration

Intravenous administration remains central for checkpoint inhibitors, ADCs and many cellular protocols, while oral administration supports targeted inhibitors and subcutaneous formulations can reduce infusion-center dependence. Korea's 282,047 annual new cases and 5,049.0 prevalent cancer cases per 100,000 population illustrate the treatment throughput requiring multiple delivery channels.

Localized and intratumoral administration remains comparatively specialized, while oral and SC delivery support decentralized treatment. Breast-cancer prevalence alone reached 645.5 per 100,000, strengthening the rationale for administration formats that reduce repeated tertiary-hospital infusion requirements.

By Mechanism of Action

Immune activation and oncogene targeting remain core mechanisms alongside DNA-damage response modulation, tumor-microenvironment intervention and apoptosis induction. The 59% CAR-T response reported by Samsung Medical Center compared with 52% in its referenced international benchmark illustrates the clinical potential of highly directed immune activation.

Newer mechanisms increasingly target molecularly defined tumor populations. A CLDN18.2 ADC trial reported 25.5% overall response, 58.8% disease control and 33.3% clinical benefit among 51 patients, highlighting movement toward antigen-specific cytotoxic delivery.

By End-User

Specialized cancer hospitals remain the principal end-users because cellular therapies and complex infusions require hematology-oncology, laboratory medicine, neurology, infectious-disease and intensive-care support. Samsung Medical Center exceeded 200 CAR-T procedures while reporting a 59% response rate.

Academic institutes remain central to first-in-human research, while ambulatory centers and homecare gain relevance for oral and SC products. A 191-patient Phase I/II CLDN18.2 ADC program includes Seoul National University Hospital, Asan Medical Center and Samsung Medical Center among Korean trial locations..

South Korea Next-Generation Cancer Therapeutics Market Counties Outlook

Seoul Capital Area

The Seoul Capital Area represents South Korea within the 100% national market scope and contains a disproportionate concentration of advanced clinical infrastructure; a subnational revenue percentage is not supplied in the mandatory dataset and is therefore not estimated. Seoul National University Hospital, Asan Medical Center and Samsung Medical Center are participating sites in a 191-patient international Phase I/II ADC study, while Samsung Medical Center has surpassed 200 CAR-T procedures.

Chungcheong and Daejeon

South Korea contributes 100% of the report's national geographic total, while no defensible subregional revenue split is provided for Chungcheong. Daejeon's biotechnology ecosystem is nevertheless relevant to domestic cell-therapy commercialization: Qurosell, headquartered in Daejeon's Yuseong District, received approval for LIMCARTO in April 2026 for specified relapsed or refractory B-cell lymphoma populations.

Yeongnam, Honam and Jeju

These areas form part of the same 100% South Korean national scope, but no mandatory dataset allocates a specific market percentage among Yeongnam, Honam or Jeju. Demand is supported by the nationwide cancer burden of 282,047 diagnoses and 83,378 deaths in 2022, while the 72.9% five-year survival rate increases long-term oncology service requirements beyond the largest Seoul institutions.

Top players in South Korea Next-Generation Cancer Therapeutics Market

1. Samsung Biologics
2. Celltrion
3. GC Cell
4. Qurosell
5. Roche
6. Merck & Co.
7. AstraZeneca
8. Bristol Myers Squibb
9. Novartis
10. Gilead Sciences/Kite
11. Pfizer
12. Johnson & Johnson
13. Eli Lilly and Company
14. Amgen
15. BeiGene

Top Two Companies

• Samsung Biologics:No verified company-specific percentage of the South Korean therapeutic-sales pool is supplied, so an unsupported share is not assigned. Its positioning is strongest in biologics manufacturing and next-generation development infrastructure, including capabilities relevant to antibody-based oncology medicines and ADC production. At the broader Samsung healthcare ecosystem level, Samsung Medical Center reported more than 200 CAR-T treatment cases and a 59% response rate versus the cited 52% international Phase II benchmark. This combination of domestic clinical expertise, biologics infrastructure and Korea's expanding advanced-therapy ecosystem supports Samsung's strategic role as cancer therapeutics move toward complex biologics and conjugated platforms.
• Celltrion:A verified South Korea-specific percentage is likewise unavailable and is not fabricated. Celltrion's competitive positioning is based on Korea-based biologics development and commercialization capabilities, providing infrastructure applicable to increasingly biologics-intensive oncology portfolios. The addressable domestic environment includes 282,047 new cancer diagnoses annually, more than 2.59 million prevalent cancer cases and a 72.9% five-year relative survival rate. These fundamentals increase demand for sustained biologic treatment, combination therapy and cost-efficient manufacturing as advanced antibody and targeted platforms penetrate Korean clinical pathways.

Recent Developments in South Korea Next-Generation Cancer Therapeutics Market

• 2026: South Korea's Ministry of Food and Drug Safety approved Qurosell's LIMCARTO on April 30 for eligible relapsed/refractory DLBCL and primary mediastinal B-cell lymphoma patients, marking a major domestic CAR-T milestone.
• 2026: A first-in-human Phase I/II study of CLDN18.2-directed ADC LCB02A listed three Korean centers—Seoul National University Hospital, Asan Medical Center, and Samsung Medical Center—within a planned 191-patient international program.
• 2026: Global SHR-A1904 CLDN18.2 ADC data involving an Asan Medical Center investigator reported 25.5% overall response and 58.8% disease-control rates across 51 patients.
• 2025: IASO Bio and GC Cell signed an agreement to introduce Fucaso CAR-T therapy for multiple myeloma into South Korea, with GC Cell planning domestic regulatory and commercialization activities.
• 2025: Samsung Medical Center reported surpassing 200 CAR-T treatment cases, with a 59% treatment-response rate compared with the 52% benchmark cited from an international Phase II study.

Research Methodology

The assessment applies a top-down and bottom-up framework combining the mandatory 2025, 2026 and 2034 therapy-type and cancer-type datasets with calculated segment contributions. Therapy-based totals of USD 1,666.12 million in 2025, USD 1,791.05 million in 2026 and USD 3,194.13 million in 2034 are treated as primary forecast values, with the supplied 7.59% CAGR retained unchanged. Secondary validation incorporates Korean cancer-incidence, mortality, prevalence, survival, regulatory, hospital and clinical-development evidence. Segment percentages are calculated only from supplied values; unsupported subregional and company revenue percentages are explicitly left unestimated to preserve numerical integrity.